ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

King's College Hospital to run Steriwave pilot

Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, confirms that King's College Hospital (KCH) will be running a pilot of its Steriwave^® light-activated antimicrobial technology. KCH, a globally recognized leader in healthcare innovation and one of London's largest teaching hospitals, will be using Steriwave as part of a quality improvement initiative pilot focused on preventing hospital-acquired infections (HAIs). The pilot at KCH is due to start later this year.

Ondine's Steriwave technology is a groundbreaking antimicrobial treatment that uses a proprietary light-activated agent to rapidly eliminate infection-causing pathogens. The agent is applied to each nostril using a nasal swab and then illuminated with a red light laser. The light activates the photodynamic agent, causing an oxidative burst that destroys infection-causing bacteria, viruses and fungi in a single, 5-minute treatment. The process works so rapidly that pathogens do not have the opportunity to develop resistance, making it a viable alternative to antibiotics.

In March 2024, Mid Yorkshire Teaching NHS Trust became the first UK institution to adopt Steriwave as standard of care for preventing surgical site infections in hip and knee surgery patients. Following its addition to the NHS Supply Chain in June 2024, Steriwave has become more accessible to hospitals and healthcare organizations across England and Wales, facilitating broader adoption of this innovative technology. 

**ENDS**

About King's College Hospital and King's College Hospital NHS Foundation Trust

King's College Hospital, located in Denmark Hill, Camberwell, is a major teaching hospital and trauma centre, renowned for its pioneering contributions to healthcare. With a rich history of over a century of innovation, King's has been at the forefront of significant medical advancements, including the UK's first bone marrow transplant and the establishment of the world's first voluntary blood donor service. King's College Hospital is managed by King's College Hospital NHS Foundation Trust.

Find out more: www.kch.nhs.uk

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies (also known as 'photodisinfection'). Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is approved in Canada and several other countries under the name Steriwave^®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.

About Steriwave

Steriwave is a groundbreaking antimicrobial treatment that uses a light-activated antimicrobial agent to rapidly eliminate a broad spectrum of pathogens, including bacteria, viruses, and fungi. The treatment is administered in a simple two-step process: first, the agent is applied to each nostril with a nasal swab, followed by illumination with a specific wavelength of red light. The light activates the agent, causing an oxidative burst that destroys pathogens within the single 5-minute treatment, offering a robust alternative to traditional antibiotics without the risk of developing resistance.

Nasal decolonization is recommended in the 2016 WHO Global guidelines for the prevention of surgical site infections,[1] and the Society for Healthcare Epidemiology of America (SHEA) guidelines, published in May 2023, recommend nasal decolonization for major surgical procedures.[2]

Enquiries: